Key End Points in Clinical Trials

Key Takeaways

• Progression-free survival and overall survival are key endpoints in multiple myeloma trials, crucial for evaluating treatment efficacy.
• Stringent eligibility criteria in clinical trials may limit their applicability to real-world scenarios, necessitating more inclusive designs.
• Incorporating diverse patient populations, including those with comorbidities, can enhance the relevance of trial outcomes.
• Real-world endpoints such as quality of life and treatment tolerability should be considered for a comprehensive understanding of therapeutic impact.